Novavax expects to make at least 2 trillion doses of COVID-19 vaccine available in 2022

September 10 (Reuters) – Vaccine developer Novavax Inc. (NVAX.O) said on Friday that at least 2 billion doses of its COVID-19 vaccine would be available by 2022.

The company, which in June announced that its vaccine was more than 90% effective in a late-stage clinical trial in the United States, said it was on track to apply for use. emergency response of his vaccine to the U.S. Food and Drug Administration. quarter quarter.

Novavax, speaking at a Morgan Stanley health conference, reiterated that it would have about 100 million doses per month by the end of the third quarter of this year and would increase to 150 million doses in the fourth quarter.

“We are already holding talks on incremental acquisitions for the second half of 2022 as well as early 2023, especially given current vaccination rates around the world,” said John Trizzino, commercial director of Novavax, adding that the reinforcement strategy would be to create additional demand for their vaccines.

In recent months, Novavax has signed several supply bids worldwide for its protein-based vaccine, including an agreement with the European Commission for 200 million doses.

Reports of Dania Nadeem and Mrinalika Roy in Bengaluru; Edited by Amy Caren Daniel

Our standards: the principles of trust of Thomson Reuters.